Woubrugge, the Netherlands, March 2nd, 2026 — ExpediteBio today announces its official launch, dedicated to accelerating the development, de-risking the progression, and enabling the early clinical validation of innovative antibody-based therapeutics. With a strong focus on supporting emerging biotech organizations through critical early-development bottlenecks, ExpediteBio combines scientific expertise, technical capabilities, and strategic support to enable faster and more cost-effective advancement toward first-in-human studies.

​

ExpediteBio complements its scientific focus with comprehensive strategic guidance and operational leadership support to help innovators navigate early-development bottlenecks. Acting as a true partner, ExpediteBio supports clients in shaping development strategies, de-risking key milestones, and aligning scientific and business objectives. Building on this strategic foundation, ExpediteBio delivers an integrated comprehensive model bridging drug development and translational biology to cell line development, analytical and functional characterization, process development, and early GMP-readiness including GMP, enabling a faster, more reliable path toward clinical validation.

​

“Biotech innovators are developing some of the most promising antibody therapies, yet many face significant challenges in translating early discoveries into clinical-ready programs,” says Richard van Rijnsoever, CEO and Co-founder of ExpediteBio. “Our mission is to reduce that complexity, helping companies move forward with robust data, strong processes, and greater confidence.”

​

Chief Strategic Alliance Officer and Co-founder Debby Vermeer-Kruijsen emphasizes the importance of partnership and infrastructure accessibility in this mission. “At ExpediteBio, we believe that scientific excellence should be accessible to all innovators, not only to those with large internal infrastructures,” says Vermeer-Kruijsen. “By building a flexible, collaborative model, we aim to empower biotech teams to advance their antibody programs faster, smarter, and with the support they need at every critical step.”

​

Strengthening the Biotech Innovation Ecosystem

With its launch, ExpediteBio positions itself as a reliable partner for companies seeking:

• Early-stage development support for antibody and protein-based therapeutics

• Faster routes to proof-of-concept through integrated analytical and process development capabilities

• De-risked progression toward first-in-human readiness

• Access to scalable, high-quality development expertise and infrastructure within the Dutch and European biotech landscape

ExpediteBio’s approach combines scientific rigor with operational agility, enabling innovators to push promising therapeutic candidates toward the clinic with greater speed and precision.

About ExpediteBio
ExpediteBio is a biotechnology company based in Woubrugge, The Netherlands, dedicated to support drug development projects with smarter, parallelized development models that reduces time, cost and risk for emerging therapeutics. Through an integrated suite of scientific, development, operational and strategic leadership services, ExpediteBio helps biotech organizations advance their programs efficiently and confidently toward clinical evaluation.

Media Contact
ExpediteBio Communications
Email: info@expeditebio.com